Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of ETI-204 in Healthy Subjects
調査の概要
詳細な説明
Protocol AH-105 is a single center, randomized, double-blind, placebo-controlled, sequential, dose escalation study. It will evaluate the safety and PK of single IV doses of ETI-204 administered to approximately 108 healthy male and female subjects. At each dose level, 30 healthy subjects, including at least 4 females, will be randomly assigned to active drug, and at least 6 healthy subjects of both genders will be randomly assigned to matching placebo.
Description of Agent: ETI-204 is a monoclonal antibody (mAb) to protective antigen (PA) from Bacillus anthracis.
The study will consist of 3 phases: Screening, Inpatient, and Outpatient Follow-up. Enrollment criteria will be determined during the 21-day Screening Phase (Visit 1), following by a 3 night inpatient phase where eligible subjects will receive a single dose of IV ETI-204 or matching placebo as described above and undergo routine safety monitoring, dermatologic assessments, and blood draws at pre-specified time points. Subjects will be discharged from the center after collection of the 48-hour PK sample. During the subsequent 70-day outpatient follow-up phase, subjects will return to the center on Days 8, 15, 29, 43 and 71 for clinical laboratory testing (hematology and clinical chemistry), physical examinations and vital signs measurements, and routine safety monitoring. Blood samples for PK and anti-drug antibodies (ADA)will also be collected. The 70 day post-dosing follow-up in this study was selected to allow characterization for the PK profile of ETI-204 and the potential development of ADA.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Kansas
-
Overland Park、Kansas、アメリカ、66211
- Quintiles
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria: Subjects who meet all of the criteria shown below may be included in the study.
- Healthy male or female subjects between 18 and 65 years of age.
- Subjects with a body mass index (BMI) > 18.5 and < 35 kg/m2.
- Female subjects of childbearing potential (not post-menopausal or surgically sterile) must have a negative urine β-hCG pregnancy test at Screening.
- Female subjects of childbearing potential (not post-menopausal or surgically sterile) must use a medically accepted method of contraception for the duration of the study, including the 70-day follow-up period. Acceptable methods of contraception include abstinence, a barrier method with spermicide, an intrauterine device (IUD) or a hormonal contraceptive (oral, transdermal, implanted, or injected) in conjunction with a barrier method.
- Male subjects must agree to practice abstinence or to use a condom with spermicide for the duration of the study, including the 70-day follow-up period.
- The subject has no clinically significant abnormalities on the clinical laboratory tests (hematology, clinical chemistry, or urinalysis) or ECG at Screening.
- Subject provides written informed consent.
Exclusion Criteria:Subjects who meet any of the criteria below will be excluded from participation in the study.
- Subject requires regular use of a medication for a chronic condition.
- Subject has a clinically significant comorbidity that would interfere with the completion of the study procedures or objectives, or would compromise the subject's safety.
- Subject has a systolic blood pressure (BP) > 140 mm Hg or a diastolic BP > 90 mm Hg.
- Subject has a systolic BP < 90 mm Hg.
- Subject has current suspected drug or alcohol abuse as specified in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (American Psychiatric Association 2000).
- Subject has a positive alcohol or drug test result at Screening and on Day -1
- Subject has received an investigational agent within 30 days or 5 half-lives (whichever is longer) of Screening.
- Subject has congenital or acquired immunodeficiency syndrome.
- Subject has a positive test for Hepatitis B (surface antigen), Hepatitis C, or human immunodeficiency virus (HIV) at Screening.
- Subject smokes > 3 cigarettes per day.
- Subject has ever had prior treatment for anthrax exposure, prior anthrax infection, prior immunization with any anthrax vaccine or prior treatment with an investigational anthrax treatment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:ETI-204
ETI-204、アンシム
|
intravenously, single dose
他の名前:
|
偽コンパレータ:プラセボ
|
intravenously, single dose
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Primary Objective
時間枠:71 days
|
To evaluate the safety of increasing doses of ETI-204 in healthy subjects
|
71 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Secondary Objective
時間枠:71 days
|
To evaluate the PK of increasing singles doses of ETI-204 in healthy subjects. To evaluate the immunogenicity of ETI-204 following IV administration in healthy subjects. |
71 days
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Eleanor A Lisbon, M.D., M.P.H、Quintiles Phase One Services
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
ETI-204, "Anthim"の臨床試験
-
Ohio State UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of Utahまだ募集していません傷やけが | 重病 | 子供のみ | 心停止、院外 | 小児の呼吸不全
-
Wyeth is now a wholly owned subsidiary of Pfizer終了しました糖尿病中国, アメリカ, カナダ, メキシコ, ロシア連邦, クロアチア, イギリス, アルゼンチン, オーストラリア, インド, 南アフリカ, ギリシャ, ウクライナ, ルーマニア, イタリア, 香港, 旧セルビア・モンテネグロ, ブラジル
-
University of Aarhus募集嚢胞性線維症 (CF) | CFTR遺伝子変異デンマーク
-
Wyeth is now a wholly owned subsidiary of Pfizer完了
-
TScan Therapeutics, Inc.募集メラノーマ | 子宮頸癌 | 頭頸部がん | HPV関連の悪性腫瘍 | 卵巣がん | HPV関連がん | HPV関連の子宮頸がん | HPV陽性の中咽頭扁平上皮がん | 非小細胞がん | HPV - 肛門性器ヒトパピローマウイルス感染症 | HPV関連腺がん | HPV関連腺扁平上皮がん | HPV関連扁平上皮がん | HPV関連肛門扁平上皮がん | HPV関連陰茎扁平上皮がん | HPV関連の外陰扁平上皮がん | HPV関連子宮頸部腺癌 | HPV関連膣腺がん | HPV陽性直腸扁平上皮がん | 肛門生殖器がん | HPV関連疣贅癌アメリカ
-
Karolinska University HospitalSwedish Foundation for Strategic Research募集